A recent study pinpoints the two leading GLP-1 manufacturers as the top pharma companies cited the most across leading AI ...
SER-155 recipients achieved immunosuppressive-free clinical response of diarrhea (a primary symptom of irEC) at Day 15 in the Investigator-Sponsored Trial (IST) conducted by Memorial Sloan Kettering C ...
The tables have turned for the U.S. biosimilars market. With more than a decade since the first FDA biosim approval, strong launches to biologic copies to AbbVie’s Humira, J&J’s Stelara and ...
Haircare experts are going for a silver metal. Emerging research says that it may be possible to reverse the effects of ...
Candel Therapeutics (CADL) shifts to late-stage oncology with CAN-2409 Phase III wins and BLA catalyst. Read here for a ...
KRAS G12C occurs in ~3%–4% of CRC, translating to a sizable metastatic population with limited options and strong rationale for KRAS G12C inhibition strategies. Dual KRAS–EGFR blockade leverages ...
Doctors around the world are taking risky gambles with cancer patients’ lives – as part of a well-intentioned, but misguided, ...
Before starting cell therapy, patients need more than hope — they need a plan. Dr. Muhammad Tariq breaks down what to expect ...
Subcutaneous amivantamab induced rapid and durable responses among patients with HPV-unrelated recurrent or metastatic head ...
SER-155 recipients achieved immunosuppressive-free clinical response of diarrhea (a primary symptom of irEC) at Day 15 in the ...
Despite substantial weight loss, most obesity drugs such as Wegovy and Mounjaro do not meaningfully improve quality of life, ...
Vertex Pharmaceuticals Incorporated’s $10B Crinetics Pharmaceuticals, Inc. buy adds PALSONIFY & a Phase 3 CAH asset. Click ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results